MX2019001958A - Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. - Google Patents
Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.Info
- Publication number
- MX2019001958A MX2019001958A MX2019001958A MX2019001958A MX2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- treating crohn
- antibody
- nkg2d antibody
- Prior art date
Links
- 208000011231 Crohn disease Diseases 0.000 title abstract 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 abstract 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377358P | 2016-08-19 | 2016-08-19 | |
| PCT/US2017/047357 WO2018035330A1 (en) | 2016-08-19 | 2017-08-17 | Methods of treating crohn's disease with an anti-nkg2d antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001958A true MX2019001958A (es) | 2019-06-13 |
Family
ID=61197073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001958A MX2019001958A (es) | 2016-08-19 | 2017-08-17 | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190292265A1 (enExample) |
| EP (1) | EP3500293A4 (enExample) |
| JP (1) | JP2019528285A (enExample) |
| KR (1) | KR20190038919A (enExample) |
| AU (1) | AU2017312049A1 (enExample) |
| CA (1) | CA3034324A1 (enExample) |
| MA (1) | MA45997A (enExample) |
| MX (1) | MX2019001958A (enExample) |
| WO (1) | WO2018035330A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2019272575A1 (en) | 2018-05-21 | 2020-12-10 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by NK cells |
| CA3105464A1 (en) | 2018-07-06 | 2020-01-09 | Cedars-Sinai Medical Center | Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures |
| CN113166762B (zh) | 2018-12-21 | 2025-01-14 | 瓦莱里奥治疗公司 | 新的偶联核酸分子及其用途 |
| TWI850365B (zh) * | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
| CN112578124A (zh) * | 2019-09-27 | 2021-03-30 | 廖睿 | 检测粪钙卫蛋白含量的试剂在制备输卵管病变筛查试剂盒中的用途 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| CN116199777B (zh) * | 2021-12-01 | 2025-01-28 | 北京免疫方舟医药科技有限公司 | 抗hNKG2D抗体及其应用 |
| IL313439A (en) | 2021-12-16 | 2024-08-01 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005082110A2 (en) * | 2004-02-26 | 2005-09-09 | Illumina Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 nkg2d에 대한 항체 및 그것의 용도 |
| CN105616410A (zh) * | 2009-07-30 | 2016-06-01 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
| WO2011082382A2 (en) * | 2009-12-31 | 2011-07-07 | The Trustees Of Columbia University In The City Of New York | Methods for detecting and regulating alopecia areata and gene cohorts thereof |
| CA2973529A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
-
2017
- 2017-08-17 KR KR1020197007550A patent/KR20190038919A/ko not_active Ceased
- 2017-08-17 US US16/325,969 patent/US20190292265A1/en not_active Abandoned
- 2017-08-17 WO PCT/US2017/047357 patent/WO2018035330A1/en not_active Ceased
- 2017-08-17 JP JP2019509555A patent/JP2019528285A/ja active Pending
- 2017-08-17 MA MA045997A patent/MA45997A/fr unknown
- 2017-08-17 MX MX2019001958A patent/MX2019001958A/es unknown
- 2017-08-17 AU AU2017312049A patent/AU2017312049A1/en not_active Abandoned
- 2017-08-17 CA CA3034324A patent/CA3034324A1/en not_active Abandoned
- 2017-08-17 EP EP17842125.1A patent/EP3500293A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018035330A1 (en) | 2018-02-22 |
| KR20190038919A (ko) | 2019-04-09 |
| MA45997A (fr) | 2019-06-26 |
| AU2017312049A1 (en) | 2019-02-21 |
| EP3500293A4 (en) | 2020-08-19 |
| EP3500293A1 (en) | 2019-06-26 |
| JP2019528285A (ja) | 2019-10-10 |
| CA3034324A1 (en) | 2018-02-22 |
| US20190292265A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
| PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
| MX384424B (es) | Agentes de unión al determinante de grupo 123 y usos de éstos. | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| PH12017500493A1 (en) | Combination therapy | |
| MX395317B (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| MX2017010336A (es) | Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn. | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| IL276896A (en) | Methods for treating Crohn's disease with a specific anti-IL23 antibody | |
| MX380557B (es) | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). | |
| MX2020004411A (es) | Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren. | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. |